Clinical Trials Logo

Spondylarthritis clinical trials

View clinical trials related to Spondylarthritis.

Filter by:

NCT ID: NCT03043846 Completed - Clinical trials for Axial Spondyloarthritis

Treat to Target Trial in Axial Spondylo Arthritis : The TICOSPA (Tight Control in Spondyloarthritis)

TICOSPA
Start date: November 30, 2016
Phase:
Study type: Observational

This is a not interventional, pragmatic, prospective, randomized (cluster) study to evaluate the potential benefit of a Treat to Target approach in comparison to routine treatment (i.e. usual care) in patients with axial spondyloarthritis.

NCT ID: NCT03039088 Completed - Fibromyalgia Clinical Trials

PREDICT-SpA - French Epidemiological Study of the Evaluation of the Impact of Fibromyalgia in the TNF Alpha Treatment Effect in Axial Spondyloarthritis in Both Anti-TNF naïve and - Experienced Patients

PREDICT_SpA
Start date: October 2, 2014
Phase:
Study type: Observational

This is a prospective observational national (France) study with 2 visits 3 months apart (baseline and 12 weeks after TNF alpha blockers initiation). The objective of recruitment is 500 SpA patients (diagnosis according to their treating rheumatologist) initiating a TNF alpha blocker. The main objective of the study is to evaluate the impact of a concomitant fibromyalgia on the anti-TNF treatment effect in axial Spondyloarthritis in both anti-TNF naïve and pre-exposed patients.

NCT ID: NCT03033095 Completed - Clinical trials for Spondylitis, Ankylosing

Prediction of the Answer to the Treatment by Biotherapies for Naive Spondyloarthritis by Combinatorial Analysis of Serum Biomarkers

PRESA
Start date: July 2016
Phase: N/A
Study type: Interventional

The aim of this trial is the caracterisation of a predicting algorithm of the answering response for patients with etanercept treatment in spondyloarthritis disease. This algorithm will help to target patients patients who have a risk / benefit important for etanercept treatment.

NCT ID: NCT03020992 Completed - Clinical trials for Axial Spondyloarthritis (axSpA)

A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU

C-VIEW
Start date: December 21, 2016
Phase: Phase 4
Study type: Interventional

The purpose of the study is to demonstrate the effect of Certolizumab Pegol (CZP) treatment on the reduction of Anterior Uveitis (AU) flares in subjects with active axial Spondyloarthritis (axSpA) and a documented history of AU.

NCT ID: NCT02998398 Completed - Clinical trials for Rheumatoid Arthritis

Evaluation of the Switch From the Original Infliximab to Its Biosimilar in Daily Practice at Cochin Hospital

SIC
Start date: October 2015
Phase:
Study type: Observational

The purpose of this study is to evaluate the effectiveness of the switch from the original infliximab ( REMICADE®) to its biosimilar (INFLECTRA®) in all the patients at Cochin hospital receiving REMICADE® for either a rheumatic, gastro-enterologic or ophthalmic condition

NCT ID: NCT02988674 Completed - Psoriatic Arthritis Clinical Trials

A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation

Adherence
Start date: December 22, 2016
Phase:
Study type: Observational

The objective of this study is to access retention rate, persistence and adherence in population of spondylarthritis (SpA) (ankylosing spondylitis (AS) and psoriatic arthritis (PsA)) participants treated with adalimumab in routine clinical settings in the Russian Federation.

NCT ID: NCT02985983 Completed - Clinical trials for Axial Spondyloarthritis

A Study of KHK4827 in Subjects With Axial Spondyloarthritis (axSpA)

Start date: March 7, 2017
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy of KHK4827 in axSpA (ankylosing spondylitis [AS] and non-radiographic axial spondyloarthritis [nr-axSpA]) subjects compared to placebo, as measured by the proportion of axSpA subjects achieving an Assessment of SpondyloArthritis international Society (ASAS) 40 response at week 16.

NCT ID: NCT02980705 Terminated - Clinical trials for Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis

Efficacy and Safety Study of SUNPG1622

Start date: November 6, 2017
Phase: Phase 2
Study type: Interventional

This is a randomized, double-Blind, placebo-controlled Phase 2a study to evaluate the efficacy and safety of SUNPG1622.

NCT ID: NCT02963506 Completed - Clinical trials for Ankylosing Spondylitis

A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis

BE AGILE
Start date: October 2016
Phase: Phase 2
Study type: Interventional

This is a study to evaluate the efficacy and safety of different doses of bimekizumab in subjects with active Ankylosing Spondylitis (AS).

NCT ID: NCT02962479 Enrolling by invitation - Clinical trials for Ankylosing Spondylitis

Is the Human Microbiome Altered in Patients With Axial Spondyloarthritis?

Start date: October 2016
Phase: N/A
Study type: Observational

This study aims to compare biological communities in stool samples obtained from age, diet and BMI-matched subjects in five study groups: subjects with ankylosing spondylitis (AS) never treated with tumor necrosing factor (TNF) inhibitors, subjects with ankylosing spondylitis previously or currently treated with TNF inhibitors, subjects with non-radiographic axial spondyloarthritis (nrSpA) never treated with tumor necrosing factor (TNF) inhibitors, subjects with non-radiographic axial spondyloarthritis previously or currently treated with TNF inhibitors and healthy participants. The differences in fecal microbiota composition will be explored using shotgun metagenomic sequencing through the University of Washington. The investigators predict that this study will confirm a significant difference between the fecal microbiota composition (FMC) of both AS and nrSpA patients and controls.